Clinical and quality-of-life outcomes associated with efgartigimod in patients with generalized myasthenia gravis transitioning from intravenous immunoglobulin.

A study published in Clinical Neurology and Neurosurgery examined outcomes in generalized myasthenia gravis (gMG) patients who switched from intravenous immunoglobulin (IVIg) to efgartigimod, a neonatal Fc receptor antagonist. Researchers assessed both clinical measures and quality-of-life indicators following the transition. The findings are relevant to PT professionals managing patients with gMG, as treatment-related changes in muscle strength and functional status can directly influence rehabilitation planning.

Read full article at PubMed / Clin Neurol Neurosurg ↗

About this summary. The text above is a short summary written for this site. The original article is hosted by PubMed / Clin Neurol Neurosurg at the link above; this site does not reproduce the full article. Verify against the source before relying on specific details.